Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not just s few shares, though - looks like about 15k. :)
I see the entire article. Thank you for your contribution.
NEWS JUST OUT:
P10 Industries, Inc. gives update on status of stock trading Market Maker has filed a Form 211 under section 15c2-11 of the Securities Exchange Act of 1934 and is awaiting approval from FINRA to resume trading in the stock DALLAS, June 07, 2017 (GLOBE NEWSWIRE) -- P10 Industries, Inc. (OTC:PIOE), formerly Active Power, Inc., today announced that a market maker has filed a Form 211 under section 15c2-11 of the Securities Exchange Act of 1934, and is now awaiting approval from FINRA. Once that approval is provided, trading in the P10 Industries stock on the OTC Pink market may commence. "I know everyone is patiently waiting for FINRA approval of the Form 211 filing so that PIOE can move from the 'gray market' to trade on OTC 'Pink,'" said Mark A. Ascolese CEO of P10 Industries. "As we previously announced, the financial condition of P10 Industries is stable, we have received the $4.5 million financing from P10/210 Investment LLC and are executing on our plan, which was approved by the bankruptcy court on May 5(th) . We will announce the FINRA approval as soon as we become aware of it."
Ready for an update. A (surprise) month without access to your investment $ is not good.
I'm with you, chemist. Why not just grant him options @ .21? Why tie it to the stock price?
Happy with mgmt generally, but this looks a bit shady.
$250 trade...maybe as someone suggested just a test between MMs?
Yet still no bid or ask on Etrade L2
ETrade won't let me. No ask or bid.
I had a bid in at .39 that did not appear on L2. Then filled 2000 @.377 though the ask was .43. OTC issue, I assume.
Just placed an order for the open with Etrade. Bid .35, ask .44. No trouble placing order.
Still tradeable on Etrade.
And I see an ask of .57. No bids yet.
ETrade L2 shows no bid or ask.
KTOV SEC filing just out:
On February 7, 2017, the Kitov Pharmaceuticals Holdings Ltd. (the “Company” or the “Registrant”) announced that it is currently being investigated by the Israeli Securities Authority (the “ISA” and the “Investigation,” or “ISA Investigation” respectively). The Company has not yet been advised by the ISA of the full scope and focus of the Investigation. However, the Company has had discussions with the ISA regarding the Investigation, and is now able to provide additional information to the Company’s investors and other stakeholders, with regard to the nature of the ISA’s concerns with respect to the Company.
Based on these discussions with the ISA, the Company now understands that the Investigation with respect to the Company relates to the Data Monitoring Committee (“DMC”) that was appointed in connection with the Company’s Phase III clinical trial of KIT-302. In connection with the clinical trial, the Company appointed an independent statistician and an orthopedist to serve as the Company’s DMC in order to review the preliminary results of the initial patient group, with respect to determining if it would be necessary to increase the number of patients to be enrolled in the clinical trial in order to demonstrate statistical validity required to meet the primary endpoint of the clinical trial.
This DMC’s responsibilities and reporting procedures were detailed in a document that was distributed to all the team members involved in the clinical trial, including the members of the DMC (the “Procedure”). According to this Procedure, a group of external independent statisticians was to receive the preliminary clinical trial results and analyze the standard deviations. The Procedure provided that the independent statisticians would send the analyzed standard deviations to both of the DMC members, who would then review the analysis, and determine whether or not the primary efficacy endpoint was met (i.e. they were to look at the statistician's printout and see if the lower limit of the 95% confidence interval for the KIT-302 drug exceed 50% of the value for amlodipine). The Company understands that the ISA is investigating the circumstances surrounding the actual dissemination of the statistical analysis to the members of the DMC, and whether or not this led to any misleading disclosures in any of the Company’s public filings.
The Company believes that the ISA’s concerns with respect to the DMC are misguided and not consistent with industry accepted U.S. Food and Drug Administration (“FDA”) regulatory requirements, nor with the procedures for the conduct of clinical trials for the purposes of New Drug Application submissions to the FDA. In addition, the Company strongly disputes the legal ramifications of any possible concerns of the ISA with respect to the Company’s disclosures in these matters.
The Company firmly believes that, (i) information relating to the circumstances surrounding the actual dissemination of the statistical analysis to the members of this DMC is not material; and, (ii) that such information was not material at the time of the Company’s announcement of the final clinical trial results. This matter had no impact whatsoever on the validity of the statistical analysis of the KIT-302 Phase III clinical trial data, which met its primary efficacy endpoint with statistical significance. Furthermore, the Company believes that the ISA is not the regulatory body authorized to evaluate the materiality of events and the completeness of public disclosures made by the Company in compliance with United States federal securities laws.
The process actually undertaken by the Company in connection with such clinical trial results, fully complied with the requirements of the FDA, and the Medicines and Healthcare products Regulatory Agency (“MHRA”) and the human ethics committee agreed-to protocol for the Phase III clinical trial of KIT-302 (“Clinical Trial Protocol”). Some clinical studies, mostly in certain types of Phase III clinical trial studies where it is required under the applicable clinical trial protocol, are overseen by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This group recommends whether or not a trial may move forward at designated check points based on access to certain data from the study. The clinical study sponsor may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. According to the KIT-302 Phase III Clinical Trial Protocol approved by the above-mentioned regulatory authorities, no data monitoring committee or data safety monitoring board or committee was required at all, and the committee named “DMC” by the Company, had no authority or power to modify or otherwise alter the conduct of the clinical trial, and was not tasked with usual data safety monitoring board or committee responsibilities related to a clinical trial. In accordance with the Clinical Trial Protocol, which had been approved by the FDA, the decision as to whether or not to add additional patients, or to stop patient enrollment, was based solely upon the statistical analysis of the preliminary data performed by an independent statistician (who was also a member of our “DMC”). The statistical analysis of the preliminary data collected in the Phase III clinical trial definitively showed that the study met the pre-specified criteria the FDA required for stopping patient enrollment and completing the final statistical analyses. The statistical analyses of the efficacy data collected in the Phase III clinical trial of KIT-302 resulted in a p-value of less than 0.001, clearly demonstrating that the Phase III clinical trial met its primary efficacy endpoint with statistical significance (any p-value less than 0.05 would have been adequate by statistical standards for proving efficacy).
2
The Investigation is still ongoing, and the Company’s officers are fully cooperating with the ISA in its Investigation. The Company’s Board of Directors has expressed its full support of Company management. The Company, its officers and Board of Directors look forward to the conclusion of this Investigation in the most expeditious manner possible.
The Company is continuing with the process of completing a New Drug Application for KIT-302, which is expected to be submitted to the FDA during the second quarter of 2017. In addition, the Company is continuing with all of its other ongoing activities, including its research and development activities in connection with KIT-302 and TyrNovo’s NT 219, further expanding its intellectual property portfolio and seeking commercialization opportunities for its therapeutic products and activities.
The additional information disclosed herein may not necessarily reflect the full scope or focus of the Investigation or the entirety of any allegations being investigated and/or which may ultimately be raised by the ISA against the Company and/or any of its officers or affiliates. At this preliminary stage, the Company is still unable, with any degree of certainty, to make any other evaluations or any other assessments with respect to the ISA Investigation or the scope of potential exposure, if any.
Great info re audit committee, EM. Thank you!
Price action seems to be very similar to what BioHunter predicted (Msg #3170) earlier this week.
Maybe that 30k ask @.40 yesterday was an effort to keep a lid on the price...
$heff maybe?
20k shares sold at 16.16 and the 22k ask at 16.01 is not touched? How is that? Major games.
For the moment, the 30k sell has disappeared.
Now 30k @ 17.99.
Don't think so, Xena. But, NTRP IR not being forthcoming about everything could lead people to think the worst.
NTRP IR created the press release.
Then, accidentally released and posted it on their website.
Then, in communication to me, pretended they had not.
That is the truth.
All he had to do was tell me that. Instead, he was vague and, I thought, misleading. Like dealing with a kid, not an IR head.
Burns me as I reduced my position by 1/2 today as a result. GLTA.
I apologize as I was unclear!
NTRPs IR man denied issuing the release in an email to me around noon:
Me: Dr. Alkon did not appear on FoxBusiness today. Can you tell me why? Thank you.
From NTRP: The company never put out a press release so I am not sure why you are asking the question
Me: MR. BENISON,
Are you stating that Neurotrope had nothing to do with the Dr. Alkon/FoxBusiness appearance press release today? If not, how was it posted on your website? (See attached screen shots.) Or, was it posted mistakenly by Neurotrope? Thank you.
From NTRP: to be honest I am trying to get to the bottom of this, but too much is really being made of this.
That's all great, but (and I meant IR when I said PR before) NTRPs IR guy first denied issuing the PR. Not 'No comment', rather 'we didn't issue that'.
How could he not be aware? Are you suggesting NTRP has such a large IR staff that this is not something he should be aware of?
If they didn't issue the PR, someone hacked their site and posted a fake PR?
All he had to say was the appearance was canceled, or rescheduled, or it was never confirmed. Instead, he did not tell me the truth (unless someone hacked into their website and posted a fake PR.)
Something is up with this FoxBusiness PR. Their PR man is being vague with me.
Earlier, he denied NTRP even put out the release. When pressed about how it got on their site (I have screen shots), he said 'too much is being made of this'.
I call BS. I get people make mistakes. But this is big business and if it was a mistake he needs to own it.
Either they had an appearance scheduled or not. If so, it was canceled or delayed. Need the truth.
Very mainstream - I have it on every morning. Can't wait!
NEWS JUST OUT via MARKETWATCH:
Sorry, can't cut and paste from my Etrade feed, but 'motions all granted' today!
'Pre-packaged bankruptcy process proceeding as planned'.
Go, PIOI.
guess not.
Thank you, don!
BTW, the news still has not shown up on my Etrade Pro screen. Bet a lot of folks haven't heard.
Do judges typically rubber stamp this kind of transaction? Hoping so.
See post from Mark, #96365, on $heff's $tation IHUB board. Great info.
I think he is saying he had a price target of $7, but now that KTOV is under investigation his rec is under review. ? Who knows, just hope there is a decent outcome here. GLTA
400k shekels = $100,000
Still a lot, but not $400,000
I bought at .28 a few months ago. The RS took place Jan. 11 and the stock price on that day was .255.
The split was 1 for 32, so the adjusted price was 8.16 right after the split. Yes, I had much fewer shares but same value day of the split.
Now, NTRP is $14.25.
Hope that answers your question. Sorry can't help with the options questions.
Reverse splits are not always bad. Case in point: NTRP, (NTRPD since the split). You just need to sit tight for a month through the process. My NTRP has almost doubled since the RS. Just need a good stock with a catalyst or two.
Good luck.
There it is! Camelot predicts 'big hammer' news drop after close today.
And this will be deleted too, no doubt.
11.77M per Etrade @ $7.55
Exactly, a billion?! Some kind of symbolic poison pill?